June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema
Author Affiliations & Notes
  • Stuart Williams
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Rozemarijn S Verhoeven
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Dustin Melton
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Janet Tully
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Sanjib Das
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • RiLee Robeson
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Andres Garcia
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Mari Yang
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Benjamin R Yerxa
    Envisia Therapeutics, Raleigh, North Carolina, United States
  • Footnotes
    Commercial Relationships   Stuart Williams, Envisia Therapeutics (E); Rozemarijn Verhoeven, Envisia Therapeutics (E); Dustin Melton, Envisia Therapeutics (E); Janet Tully, Envisia Therapeutics (E); Sanjib Das, Envisia Therapeutics (E); RiLee Robeson, Envisia Therapeutics (E); Andres Garcia, Envisia Therapeutics (E); Mari Yang, Envisia Therapeutics (E); Benjamin Yerxa, Envisia Therapeutics (E)
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4457. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stuart Williams, Rozemarijn S Verhoeven, Dustin Melton, Janet Tully, Sanjib Das, RiLee Robeson, Andres Garcia, Mari Yang, Benjamin R Yerxa; Nonclinical Development of An Intravitreal Extended Release Implant for the Treatment of Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4457.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic macular edema (DME) is a leading cause of vision loss. Corticosteroid use in DME patients is effective but has been limited by available treatments. An extended release biodegradable IVT implant, which delivers a decreased dose of dexamethasone in a linear manner over approximately 6 months while still achieving efficacy, could reduce cataract and IOP elevation rates associated with current therapies.

Methods : ENV1105 was designed for intravitreal delivery using novel nano and microparticle PRINT technology to release dexamethasone with a near zero-order release rate over approximately 6 months. Drug content and in-vitro release were measured by RP-HPLC. In vitro release rates were measured at 37C in 1X PBS, pH 7.4 with 0.1% triton X-100. Pharmacokinetics and tolerability of ENV1105 or Ozurdex were assessed in the albino rabbit for up to 3 months post-dose. Ocular matrices, remaining implants, and plasma were processed and analyzed by LC-MS/MS, and rabbits were examined via slit lamp biomicroscopy and indirect ophthalmoscopy.

Results : Extended release dexamethasone implants were fabricated with a high degree of mass and drug content uniformity and a low degree of implant to implant variability in drug release. In vitro data demonstrated a near zero-order release rate up to 6 months. For ENV1105, therapeutically relevant dexamethasone concentrations were present in target tissues of retina, choroid, and vitreous at all time points studied, while anterior and systemic exposure was not quantifiable. Posterior segment tissue concentrations following Ozurdex administration were generally not quantifiable at Month 3, and dexamethasone was quantifiable in aqueous humor and plasma through Month 1.

Conclusions : ENV1105 was developed with uniform size, shape, dose content, and a dexamethasone release profile of over 6 months. Intravitreal administration of a dose sparing, uniformly releasing dexamethasone implant produced extended delivery to the posterior target tissues with no quantifiable anterior or systemic exposure and excellent ocular tolerability, and may thus decrease the risk of adverse effects.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×